Cargando…
772. Access Denied: Impact of Insurance Denials for High-Cost Outpatient Parenteral Antimicrobial Therapy
BACKGROUND: Outpatient parenteral antimicrobial therapy (OPAT) allows patients to receive prolonged antimicrobial therapy while reducing the length of hospitalization and healthcare costs. In the United States, most public and private insurance companies require prior authorization (PA) for OPAT. Th...
Autores principales: | Bianchini, Monica L, Kenney, Rachel, Lentz, Robyn, Zervos, Marcus, Malhotra, Manu, Davis, Susan L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811214/ http://dx.doi.org/10.1093/ofid/ofz360.840 |
Ejemplares similares
-
Forgetting having denied: The “amnesic” consequences of denial
por: Otgaar, Henry, et al.
Publicado: (2017) -
Access Denied
por: Goehl, Thomas J.
Publicado: (2007) -
Denying the Truth Does Not Change the Facts: A Systematic Analysis of Pseudoscientific Denial of Complex Regional Pain Syndrome
por: Bharwani, K D, et al.
Publicado: (2021) -
1301 Outpatient Parenteral Antimicrobial Therapy (OPAT) in Intravenous Drug Users (IVDUs): Epidemiology and Outcomes
por: Papalekas, Eleni, et al.
Publicado: (2014) -
1027. Outpatient Parenteral Antimicrobial Therapy (OPAT) in Injection Drug Users (IDUs): Is It Safe?
por: Rizvi, Hira, et al.
Publicado: (2018)